Company Filing History:
Years Active: 2018-2022
Title: Michael Ray Schlabach, Jr: Innovator in Cancer Treatment
Introduction
Michael Ray Schlabach, Jr. is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented technologies. With a total of 2 patents, Schlabach is recognized for his work in developing novel therapies aimed at combating various forms of cancer.
Latest Patents
Schlabach's latest patents include groundbreaking advancements in cancer treatment. One of his patents focuses on "Compositions and methods to treat cancer." This disclosure provides novel personalized therapies, kits, transmittable forms of information, and methods for treating patients with cancer, particularly those amenable to therapeutic treatment with inhibitors. The patent also includes kits and methods for screening candidate inhibitors and associated treatment methods.
Another significant patent is titled "Organic compositions to treat beta-catenin-related diseases." This patent relates to RNAi agents that are useful in treating Beta-Catenin-related diseases, including various cancers such as colorectal cancer, breast cancer, and melanoma, among others. The invention utilizes a therapeutically effective amount of an RNAi agent to target Beta-Catenin, addressing a wide range of diseases and conditions.
Career Highlights
Throughout his career, Schlabach has worked with notable companies in the pharmaceutical industry, including Novartis AG and Arrowhead Pharmaceuticals, Inc. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.
Collaborations
Schlabach has collaborated with esteemed colleagues in his field, including Frank Peter Stegmeier and Eric Billy. These collaborations have further enhanced his research and development efforts in cancer treatment.
Conclusion
Michael Ray Schlabach, Jr. is a distinguished inventor whose work in cancer treatment has the potential to transform patient care. His innovative patents and collaborations reflect his commitment to advancing medical science and improving therapeutic options for patients facing cancer.